



Shanghai MediPharm Biotech



Shanghai MediPharm Biotech is a wholly-owned subsidiary of Medipharm Biotech Biopharmaceutical Ltd (Bermuda) focused on becoming China's leading oncology biopharma by providing novel, antibody-based, targeted radio immunotherapy for malignant cancers. Following 15 years of R&D in antibody related biopharmaceuticals, the company has a strong intellectual property portfolio, including Vivatuxin®, a chimeric tumor necrosis therapy approved by China's State Food and Drug Administration for lung cancer and launched in 2007, as well as other candidates in radio immunotherapy. Through a strategic marketing collaboration study with the Ministry of Health of China currently covering 101 hospitals, the company has agreements to supply 20,000 doses of Vivatuxin®, priced at \$3,000 each, used for the treatment of advanced lung cancer patients, who have previously failed at least one course of chemotherapy, and is negotiating collaboration with additional 50 hospitals. Furthermore, as the first radio immunotherapy for solid tumors in the world and a potential therapy for all malignant solid tumors, Vivatuxin® is undergoing Phase III clinical study registrations for glioma and liver cancer, as well as preclinical trials for colorectal and breast cancers. Finally, the company has two exclusive licenses in radio immunotherapy technology platforms from University of Southern California Cancer Therapeutic Lab, namely Lym-1 for non-Hodgkin lymphoma, which started Phase I clinical trials in 2010, and TNT fusion protein technology for solid tumors. Currently, MediPharm has a staff of 53 professionals, and with 105,000 square feet GMP-approved world class manufacturing facilities, which include a 500L B. Braun bioreactor, the company has the capacity to produce 100,000 drug doses per year.

Any offering of shares is highly speculative and involves high risks, including particularly the lack of investment liquidity, as well as expected dilution, current lack of profitability, potentially high levels of long term debt and intense competition within the industry, among others.

SHARES ARE NOT PUBLICLY TRADED

FINANCIAL STATEMENT HIGHLIGHTS

REVENUE: \$286 thousand
NET INCOME: (\$2.1 million)

All figures for twelve months ended December 31, 2009

FINANCIAL PROJECTIONS

MediPharm plans to invest in Radiation-Protective Facilities (RPFs) in 150 China Tier 3 hospitals, with each hospital requiring investment of \$75,000 for a total of \$11.3 million. Vivatuxin® is expected to generate \$45.1 million revenue and \$13.8 million net profit in 2011, \$92.8 million revenue and \$36.1 million net profit in 2012, and \$143.3 million revenue and \$52.1 million net profit in 2013.

CHINA'S ONCOLOGY MARKET

Accounting for approximately 20% of the nation's total health expenditure, the Chinese oncology market is characterized by limited therapies and large unmet medical need. With more than 3 million new cancer patients each year, cancer is the number one cause of death in China. **Fortified by healthy economic development and growing disposable income, China is on track to become the world's 3rd largest pharmaceutical market by 2012, and China is now home to an especially strong oncology market, which had reached \$14.6 billion in 2009 and is now maintaining high growth of more than 20%, according to a 2010 report by IMS Health, the world's leading provider of market intelligence to the pharmaceutical and healthcare industries operating in more than 100 countries.**

Lung cancer is the most common type of cancer among all malignant diseases, with about 500,000 new patients each year and a 5-year survival rate of only 14% due to limited efficacy of traditional therapies.



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the Wall-Street Research Small Cap Conference Book, which this is a part of, or the www.WallStreetResearch.org website.